FDA’s Growing Use of AI and What It Means for Clinical Research and eTMF

FDA’s Growing Use of AI and What It Means for Clinical Research and eTMF

The FDA’s recent announcement regarding Elsa 4.0 and the new HALO platform clearly shows that artificial intelligence is becoming an important part of the future of regulatory operations, clinical research oversight, and pharmaceutical compliance.

As someone working in the eTMF and TMF quality field, I find this development very interesting because it confirms that AI is no longer just a future concept. It is now becoming part of real-world regulatory workflows.

What Is Elsa 4.0?

Elsa 4.0 is the FDA’s internal AI assistant designed to help FDA employees work more efficiently. The platform supports scientific reviewers, investigators, compliance teams, and other FDA staff by helping them analyze information faster and improve workflow efficiency.

Some of the major capabilities mentioned by the FDA include:

• Creating workflow-specific AI agents
• Data analysis and visualization
• Voice-to-text dictation
• Converting scanned documents into searchable text
• Faster search and retrieval of regulatory information
• Supporting inspections and scientific reviews

The FDA has also stated that Elsa operates within a secure environment and still requires human review and oversight for regulatory activities.

What Is HALO?

As of May 2026, HALO stands for Harmonized AI & Lifecycle Operations, a next-generation data platform developed by the U.S. Food and Drug Administration (FDA). Along with Elsa 4.0, the FDA also introduced HALO, a centralized data platform designed to combine approximately 40 FDA systems, databases, and portals into one searchable environment.

This type of integration can significantly improve:

• Information retrieval
• Data traceability
• Inspection support
• Regulatory review timelines
• Cross-platform searching
• Operational efficiency

Why This Matters to the eTMF and Clinical Research Industry

From an eTMF and clinical operations perspective, these developments are very important.

The clinical research industry already manages extremely large volumes of documents and metadata, along with quality checks, inspection readiness activities, and compliance oversight. AI has the potential to support many of these activities in a more efficient and proactive way.

Potential areas where AI can support eTMF operations include:

• Inspection readiness
• Metadata quality review
• Document classification
• Completeness checks
• Gap analysis
• Risk identification
• Duplicate detection
• Misfiling detection
• TMF quality review support
• Audit trend analysis

However, one important point remains very clear: AI should support human decision-making, not replace it.

Important FDA Reminder About AI Oversight

Recently, the FDA also issued a Warning Letter in which investigators noted that a company relied heavily on AI-generated procedures and regulatory content without proper human review.

One of the most important observations from that Warning Letter was that AI-generated documents must still be reviewed, verified, and approved by qualified personnel before being used within regulated GxP operations.

This is a very important message for the entire industry.

AI can improve speed and efficiency, but compliance responsibility still rests with the organization, the quality unit, and subject matter experts.

AI Opportunities Within eTMF and Clinical Research

Across the clinical research and eTMF industry, organizations are actively exploring how AI can support TMF quality, compliance oversight, and inspection readiness activities in a controlled and compliant manner.

Some of the areas where AI can bring value include:

• AI-supported metadata quality checks
• Risk scoring of critical TMF documents
• AI tagging and intelligent content keyword identification
• Cross-verification of related submitted documents, including:
  • Visit logs vs. monitoring visit reports
  • FDA Form 1572 vs. PI/Sub-I CVs, medical licenses (MLs), and financial disclosure forms (FDFs)
  • IRB approvals vs. site activation
  • ICF version dates vs. enrollment dates
  • Training dates vs. first study activity
  • Regulatory, IRB, and IEC submission and approval correspondence
• TMF completeness review support
• Missclassification and misfiled documents filing accuracy checks
• Duplicate document detection
• AI-driven QC action recommendations
• Audit and quality review support
• Inspection readiness preparation and gap analysis
• Trend analysis and identification of recurring quality issues
• Faster identification of missing or inconsistent essential documents
• Timeliness of filing may become easier to trend and monitor through analytics
• Vendor oversight documentation and traceability may become easier to analyze during quality review activities through the use of AI

The key objective is not to replace quality reviewers or TMF SMEs, but rather to help teams work more efficiently while still maintaining:

• Human oversight
• Audit trails
• Regulatory compliance
• GxP expectations
• Inspection defensibility

Final Thoughts

The FDA’s move toward AI-enabled platforms like Elsa 4.0 and HALO clearly shows the direction the industry is heading.

AI will continue to become more integrated into clinical research, regulatory affairs, and eTMF operations. At the same time, organizations must ensure that AI is implemented with proper governance, validation, oversight, and compliance controls.

In my opinion, the future of AI in pharma and clinical research should always follow one important principle: “Human Reviewed and Compliance Controlled.”

Shah Ashraf
Senior TMF Consultant, eClinical Strategy & Solutions